MiR-92a Family: A Novel Diagnostic Biomarker and Potential Therapeutic Target in Human Cancers
Authors:
Open Access
- 1 October 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 6, 98
Abstract
Purpose: This study tried to explore whether members of miR-92a family contribute to early diagnosis and prognosis for human cancers and how they work. Methods: Integrated meta-analysis retrieved from public repositories was employed to assess the clinical roles of the miR-92a family for cancer diagnosis and prognosis. Expression level of miR-92a was detected by the TCGA database and was confirmed by non-small-cell lung cancer (NSCLC) tissues. Targets of miR-92a were predicted using starbase, and validated by dual luciferase assay. Correlation between miR-92a and the target gene was assessed by linkedOmics while expression of the target gene and its role in cancer prognosis were analyzed with UALCAN and Gepia. Results: We recognized the miR-92a family could serve as a potential diagnostic biomarker with a pooled sensitivity of 0.85 [0.81–0.88] and specificity of 0.86 [0.83–0.90]. The overall hazard ratio (HR) was 2.26 [95% CI: 1.70–3.00] for high expression groups compared to low expression groups. Expression of miR-92a was identified to be upregulated in NSCLC, especially in lung squamous cell carcinoma (LUSC). Results from starbase and dual luciferase assay indicated the regulator of G-protein signaling 3 (RGS3) was a direct target of miR-92a. Statistical negative correlation was found for the expression of miR-92a and RGS3. In addition, expression of RGS3 was downregulated in NSCLC and patients with the high expression had a poor prognosis (HR = 1.3) for LUSC patients. However, results were to the contrary for lung adenocarcinoma (HR = 0.7). Conclusion: This study revealed that miR-92a family could be ideal biomarkers for cancer diagnosis and prognosis, which might function through targeting RGS3.Keywords
Funding Information
- National Natural Science Foundation of China (81502878, 81773524)
This publication has 44 references indexed in Scilit:
- The noncoding RNA HOXD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinomaMolecular Cancer, 2017
- MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasisInternational Journal of Oncology, 2017
- Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcomaOncotarget, 2017
- Overexpression of miR-92a promotes the tumor growth of osteosarcoma by suppressing F-box and WD repeat-containing protein 7Gene, 2017
- Prognostic role of microRNA-25 in cancers: evidence from a meta-analysis.2015
- A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancerBritish Journal of Cancer, 2014
- Non‐coding RNAs in cancer initiation and progression and as novel biomarkersMolecular Oncology, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- RGS3 Is a GTPase-Activating Protein for Giαand Gqαand a Potent Inhibitor of Signaling by GTPase-Deficient Forms of Gqαand G11αMolecular Pharmacology, 2000
- Regulator of G Protein Signaling RGS3T Is Localized to the Nucleus and Induces ApoptosisJournal of Biological Chemistry, 2000